{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:58:14Z","timestamp":1775476694928,"version":"3.50.1"},"reference-count":39,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EuroSarc","award":["278742"],"award-info":[{"award-number":["278742"]}]},{"name":"EuroSarc","award":["17527"],"award-info":[{"award-number":["17527"]}]},{"name":"EIT Health","award":["278742"],"award-info":[{"award-number":["278742"]}]},{"name":"EIT Health","award":["17527"],"award-info":[{"award-number":["17527"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The neoplastic \u201cstromal\u201d cells in giant cell tumor of bone (GCTB) harbor a mutation in the H3F3A gene, which causes alterations in the epigenome. Current systemic targeted therapies, such as denosumab, do not affect the neoplastic cells, resulting in relapse upon treatment discontinuation. Therefore, this study examined whether targeting the epigenome could eliminate the neoplastic cells from GCTB. We established four novel cell lines of neoplastic \u201cstromal\u201d cells that expressed the H3F3A p.G34W mutation. These cell lines were used to perform an epigenetics compound screen (n = 128), which identified histone deacetylase (HDAC) inhibitors as key epigenetic regulators in the neoplastic cells. Transcriptome analysis revealed that the neoplastic cells expressed all HDAC isoforms, except for HDAC4. Therefore, five HDAC inhibitors targeting different HDAC subtypes were selected for further studies. All GCTB cell lines were very sensitive to HDAC inhibition in both 2D and 3D in vitro models, and inductions in histone acetylation, as well as apoptosis, were observed. Thus, HDAC inhibition may represent a promising therapeutic strategy to eliminate the neoplastic cells from GCTB lesions, which remains the paramount objective for GCTB patients who require life-long treatment with denosumab.<\/jats:p>","DOI":"10.3390\/cancers14194708","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T21:23:27Z","timestamp":1664313807000},"page":"4708","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic \u201cStromal\u201d Cells from Giant Cell Tumors of Bone"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-9818","authenticated-orcid":false,"given":"Sanne","family":"Venneker","sequence":"first","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-3801","authenticated-orcid":false,"given":"Robin","family":"van Eenige","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwine B.","family":"Kruisselbrink","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-5469","authenticated-orcid":false,"given":"Ieva","family":"Palubeckait\u0117","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9047","authenticated-orcid":false,"given":"Alice E.","family":"Taliento","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge H.","family":"Briaire-de Bruijn","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-8104","authenticated-orcid":false,"given":"Pancras C. W.","family":"Hogendoorn","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7656","authenticated-orcid":false,"given":"Michiel A. J.","family":"van de Sande","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-5508","authenticated-orcid":false,"given":"Hailiang","family":"Mei","sequence":"additional","affiliation":[{"name":"Sequencing Analysis Support Core (SASC), Leiden University Medical Center, 2333 ZC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-0481","authenticated-orcid":false,"given":"Judith V. M. G.","family":"Bov\u00e9e","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-4245","authenticated-orcid":false,"given":"Karoly","family":"Szuhai","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"ref_1","unstructured":"WHO Classification of Tumours Editorial Board (2020). Giant Cell Tumour of Bone. WHO Classification of Tumours\u2013Soft Tissue and Bone Tumours, IARC Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","article-title":"The Clinical Approach Toward Giant Cell Tumor of Bone","volume":"19","author":"Dijkstra","year":"2014","journal-title":"Oncologist"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-014-1666-7","article-title":"Gene Expression Profiling of Giant Cell Tumor of Bone Reveals Downregulation of Extracellular Matrix Components Decorin and Lumican Associated with Lung Metastasis","volume":"465","author":"Lieveld","year":"2014","journal-title":"Virchows Arch."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1359\/jbmr.080905","article-title":"CD33+ CD14- Phenotype Is Characteristic of Multinuclear Osteoclast-like Cells in Giant Cell Tumor of Bone","volume":"24","author":"Forsyth","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.orthres.2004.06.018","article-title":"Recruitment of Osteoclast Precursors by Stromal Cell Derived Factor-1 (SDF-1) in Giant Cell Tumor of Bone","volume":"23","author":"Liao","year":"2005","journal-title":"J. Orthop. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jcp.2011.090852","article-title":"The Immunophenotype of Osteoclasts and Macrophage Polykaryons","volume":"64","author":"Maggiani","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1309\/BPET-F2PE-P2BD-J3P3","article-title":"RANK (Receptor Activator of Nuclear Factor Kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of Bone","volume":"117","author":"Roux","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/ng.2814","article-title":"Distinct H3F3A and H3F3B Driver Mutations Define Chondroblastoma and Giant Cell Tumor of Bone","volume":"45","author":"Behjati","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/PAS.0000000000000512","article-title":"Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma","volume":"39","author":"Cleven","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cjp2.13","article-title":"Diagnostic Value of H3F3A Mutations in Giant Cell Tumour of Bone Compared to Osteoclast-Rich Mimics","volume":"1","author":"Presneau","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41598-019-42611-1","article-title":"Characterization of Three Novel H3F3A-Mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway","volume":"9","author":"Seeling","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2019.02.001","article-title":"Knock-down of Oncohistone H3F3A-G34W Counteracts the Neoplastic Phenotype of Giant Cell Tumor of Bone Derived Stromal Cells","volume":"448","author":"Fellenberg","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/2159-8290.CD-20-0461","article-title":"H3.3 G34w Promotes Growth and Impedes Differentiation of Osteoblast-like Mesenchymal Progenitors in Giant Cell Tumor of Bone","volume":"10","author":"Khazaei","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Forsyth, R.G., Kren\u00e1cs, T., Athanasou, N., and Hogendoorn, P.C.W. (2021). Cell Biology of Giant Cell Tumour of Bone: Crosstalk between m\/Wt Nucleosome H3.3, Telomeres and Osteoclastogenesis. Cancers, 13.","DOI":"10.3390\/cancers13205119"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jmb.2018.04.014","article-title":"Histone H3.3 G34 Mutations Alter Histone H3K36 and H3K27 Methylation in Cis","volume":"430","author":"Shi","year":"2018","journal-title":"J. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1038\/s41467-020-18955-y","article-title":"Globally Altered Epigenetic Landscape and Delayed Osteogenic Differentiation in H3.3-G34W-Mutant Giant Cell Tumor of Bone","volume":"11","author":"Lutsik","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27354","DOI":"10.1073\/pnas.2006076117","article-title":"Histone H3.3 G34 Mutations Promote Aberrant PRC2 Activity and Drive Tumor Progression","volume":"117","author":"Jain","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00428-012-1235-x","article-title":"Smooth Muscle Actin Expression in Primary Bone Tumours","volume":"460","author":"Hemingway","year":"2012","journal-title":"Virchows Arch."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Balke, M., Campanacci, L., Gebert, C., Picci, P., Gibbons, M., Taylor, R., Hogendoorn, P., Kroep, J., Wass, J., and Athanasou, N. (2010). Bisphosphonate Treatment of Aggressive Primary, Recurrent and Metastatic Giant Cell Tumour of Bone. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-462"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"889-e421","DOI":"10.1634\/theoncologist.2019-0280","article-title":"Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial","volume":"24","author":"Lipplaa","year":"2019","journal-title":"Oncologist"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000645","article-title":"Current Concepts in the Treatment of Giant Cell Tumour of Bone","volume":"32","author":"Dijkstra","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"151882","DOI":"10.1016\/j.anndiagpath.2021.151882","article-title":"Clinicopathologic and Molecular Features of Denosumab-Treated Giant Cell Tumour of Bone (GCTB): Analysis of 21 Cases","volume":"57","author":"Yang","year":"2022","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth Rate Inhibition Metrics Correct for Confounders in Measuring Sensitivity to Cancer Drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Franceschini, N., Oosting, J., Tamsma, M., Niessen, B., De Bruijn, I.B., van den Akker, B., Kruisselbrink, A.B., Palubeckait\u0117, I., Bov\u00e9e, J.V.M.G., and Cleton-jansen, A.M. (2021). Targeting the Nad Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low Naprt Expression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126273"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Venneker, S., Kruisselbrink, A.B., Briaire-de Bruijn, I.H., de Jong, Y., van Wijnen, A.J., Danen, E.H.J., and Bov\u00e9e, J.V.M.G. (2019). Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status. Cancers, 11.","DOI":"10.3390\/cancers11121918"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Balke, M., Neumann, A., Szuhai, K., Agelopoulos, K., August, C., Gosheger, G., Hogendoorn, P.C.W., Athanasou, N., Buerger, H., and Hagedorn, M. (2011). A Short-Term in Vivo Model for Giant Cell Tumor of Bone. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-241"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s13577-020-00415-w","article-title":"Establishment and Characterization of NCC-GCTB1-C1: A Novel Patient-Derived Cancer Cell Line of Giant Cell Tumor of Bone","volume":"33","author":"Noguchi","year":"2020","journal-title":"Hum. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s13577-021-00579-z","article-title":"Establishment and Characterization of Novel Patient-Derived Cell Lines from Giant Cell Tumor of Bone","volume":"34","author":"Yoshimatsu","year":"2021","journal-title":"Hum. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s13577-021-00639-4","article-title":"Establishment and Characterization of the NCC-GCTB4-C1 Cell Line: A Novel Patient-Derived Cell Line from Giant Cell Tumor of Bone","volume":"35","author":"Ono","year":"2022","journal-title":"Hum. Cell"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mahdal, M., Neradil, J., Mudry, P., Paukovcekova, S., Zambo, I.S., Urban, J., Macsek, P., Pazourek, L., Tomas, T., and Veselska, R. (2021). New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFR\u03b2 Signaling. Cancers, 13.","DOI":"10.3390\/cancers13143543"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1152\/physrev.00004.2015","article-title":"Histone Deacetylases in Bone Development and Skeletal Disorders","volume":"95","author":"Bradley","year":"2015","journal-title":"Physiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1083\/jcb.201403138","article-title":"HDAC4 Integrates PTH and Sympathetic Signaling in Osteoblasts","volume":"205","author":"Obri","year":"2014","journal-title":"J. Cell Biol."},{"key":"ref_33","first-page":"106","article-title":"Personalized Medicine Modality Based on Patient-Derived Xenografts from a Malignant Transformed GCTB Harboring H3F3A G34W Mutation","volume":"29","author":"Yafei","year":"2021","journal-title":"J. Orthop. Transl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat","volume":"57","author":"Westerman","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical Toxicities of Histone Deacetylase Inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0024-3205(03)00434-X","article-title":"Expression of VEGF and MMP-9 in Giant Cell Tumor of Bone and Other Osteolytic Lesions","volume":"73","author":"Kumta","year":"2003","journal-title":"Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"De Vita, A., Vanni, S., Miserocchi, G., Fausti, V., Pieri, F., Spadazzi, C., Cocchi, C., Liverani, C., Calabrese, C., and Casadei, R. (2022). A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020372"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","article-title":"Lenvatinib with Etoposide plus Ifosfamide in Patients with Refractory or Relapsed Osteosarcoma (ITCC-050): A Multicentre, Open-Label, Multicohort, Phase 1\/2 Study","volume":"22","author":"Gaspar","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4708\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:40:41Z","timestamp":1760143241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":39,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194708"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194708","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}